Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-05-06 20:00:35 ET · period of report 2026-05-05 · accession 0001680739-26-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-05-06 20:00 | 2026-05-05 | TVTX | Baynes Roy D. | Dir | M - OptEx | $18.27 | +4,500 | 42.0K | +12% | +$82.2K |
| DT | 2026-05-06 20:00 | 2026-05-05 | TVTX | Baynes Roy D. | Dir | S - Sale+OE | $46.65 | -4,500 | 37.5K | -11% | -$209.9K |
| DT | 2026-05-06 20:00 | 2026-05-05 | TVTX | Baynes Roy D. | Dir | M - OptEx | $0.00 | -4,500 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-05 | M | A | 4,500 | $18.27 | 42,000 | D | — | — | |
| 2 | Common | Common Stock | 2026-05-05 | S | D | 4,500 | $46.65 | 37,500 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. |
| 3 | Derivative | Stock option (right to buy) | 2026-05-05 | M | D | 4,500 | $0.00 | 0 | D | $18.27 · — to 2031-05-14 | 4,500 Common Stock | (F2) The stock option is fully vested and exercisable. |